Have a feature idea you'd love to see implemented?
Let us know!
AQST Aquestive Therapeutics Inc
Price (delayed)
$4.56
Market cap
$415.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.46
Enterprise value
$457.31M
Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan,
Highlights
The company's gross profit has surged by 54% YoY and by 2.3% QoQ
Aquestive Therapeutics's gross margin has increased by 25% YoY
AQST's equity has surged by 56% year-on-year but it is down by 28% since the previous quarter
AQST's net income has dropped by 191% year-on-year and by 37% since the previous quarter
The EPS has dropped by 130% year-on-year and by 28% since the previous quarter
Key stats
What are the main financial stats of AQST
Market
Valuations
Earnings
Shares outstanding
91.18M
Market cap
$415.77M
Enterprise value
$457.31M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
7.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.76
Revenue
$58.9M
EBIT
-$19.26M
EBITDA
-$18.23M
Free cash flow
-$34.37M
Per share
Balance sheet
Liquidity
EPS
-$0.46
Free cash flow per share
-$0.38
Book value per share
-$0.5
Revenue per share
$0.65
TBVPS
$1.21
Total assets
$109.96M
Total liabilities
$155.38M
Debt
$119.43M
Equity
-$45.42M
Working capital
$81.42M
Debt to equity
-2.63
Current ratio
6.37
Quick ratio
5.78
Net debt/EBITDA
-2.28
Margins
Efficiency
Dividend
EBITDA margin
-30.9%
Gross margin
69.4%
Net margin
-59.8%
Operating margin
-35.8%
Return on assets
-34%
Return on equity
N/A
Return on invested capital
-14.7%
Return on capital employed
-20.3%
Return on sales
-32.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AQST stock price
How has the Aquestive Therapeutics stock price performed over time
Intraday
1.11%
1 week
2.7%
1 month
-10.59%
1 year
123.53%
YTD
125.74%
QTD
-8.43%
Financial performance
How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$58.9M
Gross profit
$40.87M
Operating income
-$21.1M
Net income
-$35.19M
Gross margin
69.4%
Net margin
-59.8%
AQST's net income has dropped by 191% year-on-year and by 37% since the previous quarter
The net margin has plunged by 137% YoY and by 36% from the previous quarter
The company's gross profit has surged by 54% YoY and by 2.3% QoQ
The operating income has decreased by 39% from the previous quarter but it has increased by 3.7% YoY
Growth
What is Aquestive Therapeutics's growth rate over time
Valuation
What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
7.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.76
The EPS has dropped by 130% year-on-year and by 28% since the previous quarter
AQST's equity has surged by 56% year-on-year but it is down by 28% since the previous quarter
AQST's P/S is 143% above its 5-year quarterly average of 2.9 and 38% above its last 4 quarters average of 5.1
Aquestive Therapeutics's revenue has increased by 23% YoY
Efficiency
How efficient is Aquestive Therapeutics business performance
The company's return on invested capital has shrunk by 167% YoY and by 46% QoQ
The return on sales has dropped by 160% year-on-year and by 49% since the previous quarter
AQST's ROA has dropped by 65% year-on-year and by 20% since the previous quarter
Dividends
What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AQST.
Financial health
How did Aquestive Therapeutics financials performed over time
The company's total assets is 29% lower than its total liabilities
The company's total assets has surged by 85% YoY but it fell by 7% QoQ
Aquestive Therapeutics's quick ratio has decreased by 16% QoQ
AQST's debt to equity has dropped by 148% year-on-year but it is up by 20% since the previous quarter
AQST's equity has surged by 56% year-on-year but it is down by 28% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.